Kinomica Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$5.58M
- Investors
-
11
Kinomica General Information
Description
Developer of a phosphoproteomic diagnostic platform designed to enhance tailored treatment decisions involving anticancer drug therapies. The company's platform provides a suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can access direct activity measurements of multiple endogenous kinases and comprehensive cell signal network coverage, enabling patients to determine disease mechanisms while upscaling drug targeting and biomarker identification.
Contact Information
Website
www.kinomica.comCorporate Office
- Biohub Alderley Park
- Alderley Edge, Cheshire
- Macclesfield SK10 4TG
- England, United Kingdom
Corporate Office
- Biohub Alderley Park
- Alderley Edge, Cheshire
- Macclesfield SK10 4TG
- England, United Kingdom
Kinomica Timeline
Kinomica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 24-Jul-2024 | $5.58M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 01-Mar-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 08-Dec-2020 | Completed | Generating Revenue | |||
| 3. Grant | 03-Sep-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 10-Jul-2019 | $633K | $633K | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Jan-2016 | Completed | Generating Revenue |
Kinomica Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Ordinary | ||||||||
| B Ordinary | ||||||||
| A Ordinary | ||||||||
| B Ordinary | 56,000 | $0.000013 | $4.81 | $4.81 | 1x | $4.81 | 3.46% | |
| A Ordinary | 77,800 | $0.000013 | $4.81 | $4.81 | 1x | $4.81 | 4.8% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Kinomica Comparisons
Industry
Financing
Details
Kinomica Competitors (59)
One of Kinomica’s 59 competitors is StemiRNA Therapeutics, a Venture Capital-Backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| StemiRNA Therapeutics | Venture Capital-Backed | Shanghai, China | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| STORM Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Harness Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Kinomica Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kinomica Patents
Kinomica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202107091-D0 | Acute myeloid leukaemia midostaurin biomarkers | Inactive | 18-May-2021 | ||
| EP-4341694-A2 | Methods and kits for predicting the efficacy of midostaurin for the treatment of cancer | Pending | 18-May-2021 | ||
| US-20240261259-A1 | Methods and kits for predicting the efficacy of midostaurin for the treatment of cancer | Pending | 18-May-2021 | ||
| WO-2022243679-A2 | Methods and kits for predicting the efficacy of midostaurin for the treatment of cancer | Inactive | 18-May-2021 | ||
| WO-2022243679-A3 | Methods and kits for predicting the efficacy of midostaurin for the treatment of cancer | Inactive | 18-May-2021 | G01N33/57505 |
Kinomica Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kinomica Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mercia Ventures | Venture Capital | Minority | ||
| BGF (Financial Services) | Growth/Expansion | Minority | ||
| Longwall Ventures | Venture Capital | Minority | ||
| Puffin Point | Family Office | Minority | ||
| Innovate UK | Government | Minority |
Kinomica FAQs
-
When was Kinomica founded?
Kinomica was founded in 2016.
-
Where is Kinomica headquartered?
Kinomica is headquartered in Macclesfield, United Kingdom.
-
What is the size of Kinomica?
Kinomica has 27 total employees.
-
What industry is Kinomica in?
Kinomica’s primary industry is Biotechnology.
-
Is Kinomica a private or public company?
Kinomica is a Private company.
-
What is the current valuation of Kinomica?
The current valuation of Kinomica is .
-
What is Kinomica’s current revenue?
The current revenue for Kinomica is .
-
How much funding has Kinomica raised over time?
Kinomica has raised $13.1M.
-
Who are Kinomica’s investors?
Mercia Ventures, BGF (Financial Services), Longwall Ventures, Puffin Point, and Innovate UK are 5 of 11 investors who have invested in Kinomica.
-
Who are Kinomica’s competitors?
StemiRNA Therapeutics, etherna, STORM Therapeutics, Harness Therapeutics, and CytomX Therapeutics are some of the 59 competitors of Kinomica.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
